Set a bug to kill a bug
By Marian Turner,
Nature News
| 08. 16. 2011
Engineered bacteria that can detect and kill human pathogens could provide a new way to treat antibiotic-resistant bacteria. Using the tools of synthetic biology, researchers have given bacteria therapeutic properties unseen in any natural strain — although they won't be injected into people any time soon.
"Our study is the first example of how synthetic biology will be useful for fighting bacterial infections," says biochemical engineer Matthew Chang, an author on the paper, which is published today in Molecular Systems Biology.1
Chang and his team at Nanyang Technological University in Singapore have engineered a strain of Escherichia coli bacteria that attacks Pseudomonas aeruginosa, a bacterium that can cause lethal infections.
Pseudomonas aeruginosa competes with its own species by producing toxic proteins called pyocins. Chang's team exploited this molecular system by giving E. coli the genes for pyocin S5, which kills strains of P. aeruginosa that infect people. Because each pyocin targets only certain bacterial strains, the toxin will not kill other bacteria living in the body.
"Pyocins are the Pseudomonas bacterium's own species-specific antibiotics, so using pyocins...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...